Journal article
Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
D Rao, AB Mallick, T Augustine, C Daroqui, J Jiffry, A Merla, I Chaudhary, R Seetharam, A Sood, S Gajavelli, S Aparo, L Rajdev, A Kaubisch, J Chuy, A Negassa, JM Mariadason, R Maitra, S Goel
Oncotarget | Published : 2019
Abstract
Background: ERCC1, a component of nucleotide excision repair pathway, is known to repair DNA breaks induced by platinum drugs. We sought to ascertain if ERCC1 expression dynamics and a single nucleotide polymorphism (SNP) rs11615 are biomarkers of sensitivity to oxaliplatin therapy in patients with colorectal cancer (CRC). Methods: Western blot and qPCR for ERCC1 expression was performed from PBMCs isolated from patients receiving oxaliplatin-based therapy at specified timepoints. DNA was also isolated from 59 biorepository specimens for SNP analysis. Clinical benefit was determined using progression free survival (PFS) for metastatic CRC. Results: ERCC1 was induced in PBMC in response to ox..
View full abstract